Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

NCT07241390 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07241390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07241390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
December 1, 2025
Completion date
August 31, 2031
Enrollment
7,140 (estimated)
Sites
566

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis cardiovascular disease, chronic kidney disease